What is Belsomra (suvorexant) used for?

What is Belsomra (Suvorexant) Used For?

Belsomra (suvorexant) is FDA-approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults. 1

Mechanism of Action

• Suvorexant is a dual orexin receptor antagonist (DORA) that blocks orexin-1 and orexin-2 receptors in the lateral hypothalamus, which are responsible for promoting wakefulness. 2, 3
• By antagonizing these receptors, suvorexant reduces the drive for wakefulness and facilitates the transition to sleep, rather than forcing sedation like traditional hypnotics. 2, 3

Clinical Indications

Primary Use: Insomnia Treatment

• Suvorexant is indicated for both sleep-onset insomnia (difficulty falling asleep) and sleep-maintenance insomnia (difficulty staying asleep). 1
• The American Academy of Sleep Medicine recommends suvorexant specifically for sleep-maintenance insomnia, where it reduces wake after sleep onset by 16–28 minutes compared to placebo. 4, 5
• Suvorexant is positioned as a second-line pharmacologic option after first-line benzodiazepine receptor agonists (BzRAs) or when patients require a non-controlled substance with no abuse potential. 5, 6

Positioning in Treatment Algorithm

• Cognitive Behavioral Therapy for Insomnia (CBT-I) must be initiated before or alongside suvorexant, as behavioral therapy provides superior long-term efficacy with sustained benefits after medication discontinuation. 4, 5
• Suvorexant is appropriate when CBT-I alone is insufficient, when first-line BzRAs have failed, or when patients have a history of substance use disorder (since suvorexant has no abuse potential and is not DEA-scheduled). 5, 6

Dosing and Administration

• The recommended starting dose is 10 mg taken once nightly within 30 minutes of bedtime, with at least 7 hours remaining before planned awakening. 1
• If 10 mg is well-tolerated but ineffective after 1–2 weeks, the dose may be increased to a maximum of 20 mg. 1
• For patients taking moderate CYP3A inhibitors, start at 5 mg (maximum 10 mg); suvorexant is not recommended with strong CYP3A inhibitors. 1
• No dose adjustment is required for advanced age, though obese women have increased exposure and may require closer monitoring before dose escalation. 6, 1

Efficacy Evidence

• Meta-analysis of four randomized trials (3,076 patients) demonstrated that suvorexant significantly improves subjective time to sleep onset, subjective total sleep time, and subjective quality of sleep at 1 and 3 months. 7
• Objective polysomnography data show suvorexant increases total sleep time by approximately 10 minutes and reduces wake after sleep onset by 16–28 minutes. 4, 6

Safety Profile

• The most common adverse effect is somnolence, occurring in approximately 7% of patients (versus 3% for placebo). 6
• Other common side effects include dizziness, headaches, fatigue, and abnormal dreams. 2, 7
• FDA warnings include potential cognitive and behavioral changes (amnesia, anxiety, hallucinations), complex sleep behaviors (sleep-driving, sleep-walking), and next-day impairment. 4, 6, 1
• Suvorexant carries a lower risk of cognitive and psychomotor impairment, falls, and complex sleep behaviors compared to benzodiazepine-type agents. 4, 5
• Unlike benzodiazepines, suvorexant has no abuse potential, no withdrawal symptoms, and no rebound insomnia upon discontinuation. 2

Emerging Research Applications

• Preliminary research suggests suvorexant may acutely decrease tau phosphorylation and amyloid-β concentrations in the central nervous system, raising the possibility of repurposing for Alzheimer's disease prevention, though chronic treatment studies are needed. 8
• Suvorexant is being studied for delirium prevention in hospitalized older adults and ICU patients, with meta-analyses showing a 40–46% relative risk reduction in delirium prevalence (low-certainty evidence). 9, 10
• Exploratory studies are evaluating suvorexant for improving sleep in patients with obstructive sleep apnea, Alzheimer's disease, dementia, acute stroke, and delirium. 2, 11

Key Advantages Over Other Hypnotics

• No abuse potential or DEA scheduling, making it suitable for patients with substance use history. 5, 2
• Works through a unique mechanism (orexin antagonism) rather than GABA modulation, offering an alternative for patients who fail or cannot tolerate benzodiazepine-type agents. 2, 3
• Lower risk of falls, cognitive impairment, and complex sleep behaviors compared to traditional benzodiazepines and Z-drugs. 4, 5
• No evidence of tolerance, dependence, or rebound insomnia with chronic use. 2

Common Pitfalls to Avoid

• Do not prescribe suvorexant without concurrent CBT-I, as behavioral therapy provides more durable benefits than medication alone. 4, 5
• Avoid taking suvorexant with or soon after meals, as food delays time to effect. 1
• Do not combine suvorexant with strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin), as this markedly increases drug exposure. 1
• Discontinue immediately if complex sleep behaviors occur (sleep-driving, sleep-walking, sleep-eating). 4, 1
• Monitor for next-day impairment, especially at the 20 mg dose, which can impair driving ability for up to 11.5 hours after dosing. 4, 1